Of the eight human genes implicated in xeroderma pigmentosum, defects in XPG produce some of the most clinically diverse symptoms. These range from mild freckling to severe skeletal and neurologic abnormalities characteristic of Cockayne syndrome. Mildly affected xeroderma pigmentosum group G patients have diminished XPG endonuclease activity in nucleotide excision repair, whereas severely affected xeroderma pigmentosum group G/ Cockayne syndrome patients produce truncated XPG proteins that are unable to function in either nucleotide excision repair or the transcriptioncoupled repair of oxidative lesions. The ®rst two xeroderma pigmentosum group G patients, XP2BI and XP3BR, were reported before the relationship between xeroderma pigmentosum group G and Cockayne syndrome was appreciated. Here we provide evidence that both patients produce truncated proteins from one XPG allele. From the second allele, XP2BI generates full-length XPG of 1186 amino acids containing a single L858P substitution that has reduced stability and greatly impaired endonuclease activity. In XP3BR, a single base deletion and alternative splicing at a rare noncanonical AT± AC intron produces a 1185 amino acid protein containing 44 internal non-XPG residues. This protein is stably expressed but it also has greatly impaired endonuclease activity. These four XPG products can thus account for the severe ultraviolet sensitivity of XP2BI and XP3BR ®broblasts. These cells, unlike those from xeroderma pigmentosum group G/ Cockayne syndrome patients, are capable of limited transcription-coupled repair of oxidative lesions. Our results suggest that the L858P protein in XP2BI and the almost full-length XPG protein in XP3BR are responsible for this activity and for the absence of severe early onset Cockayne syndrome symptoms in these patients. Key words: Cockayne syndrome/DNA repair/nucleotide excision repair/transcription-coupled repair. J Invest Dermatol 118: 344±351, 2002 X PG is one of eight human genes causally implicated in xeroderma pigmentosum (XP), a rare autosomal recessive disorder characterized by acute sun sensitivity, a high incidence of skin cancers in sunexposed areas and, in some patients, progressive neurologic abnormalities (Cleaver and Kraemer, 1995; Rapin et al, 2000) . The products of seven of these genes (XPA±XPG) are involved in nucleotide excision repair (NER), the important DNA repair pathway that removes damage caused by ultraviolet (UV) light and many chemical agents. The enzymatic role of the 133 kDa XPG protein in this pathway is now well established: it is a structure-speci®c endonuclease that cuts the damaged DNA strand 3¢ to the lesion near the junction between the unpaired damaged strand and downstream undamaged duplex DNA (O'Donovan et al, 1994a; Matsunaga et al, 1995) . XPG also has a noncatalytic role in NER: its presence is required in the incision complex to permit the ERCC1-XPF heterodimer to make the 5¢-cut (Wakasugi et al, 1997; Constantinou et al, 1999) .
The group G form of XP is very rare and clinically very heterogeneous. The 10 reported cases range from mildly affected young adults whose XP diagnosis is not at all obvious (Ichihashi et al, 1985; Norris et al, 1987) to patients who died in infancy or early childhood with symptoms characteristic of a second disorder, Cockayne syndrome (CS) (Jaeken et al, 1989; Vermeulen et al, 1993; Hamel et al, 1996; Moriwaki et al, 1996; Zafeiriou et al, 2001) . These include neuronal demyelination, mental retardation, microcephaly, skeletal and retinal abnormalities, and dental caries, but no predisposition to cancer (Nance and Berry, 1992; Rapin et al, 2000) . At ®rst sight, XP-G also seems to be a not particularly cancer prone condition as only two of the reported 10 cases developed skin cancer; however, four XP-G individuals suffered from severe early onset CS and received very little UV exposure before their early demise (Jaeken et al, 1989; Hamel et al, 1996; Moriwaki et al, 1996) , and two others have very low but signi®cant NER activity that can account for their lack of severe XP symptoms (Constantinou et al, 1999) . In some very rare cases, some CS individuals have been found to carry mutations in the XPB and XPD genes. These genes encode the helicase subunits of TFIIH, a multisubunit factor that is essential for both NER and transcription by RNA polymerase II (Frit et al, 1999) . Most CS patients, however, belong to the CS-A and CS-B complementation groups and possess no XP overlap. The functions of the corresponding CSA and CSB proteins are not yet established but cells from these patients are defective in transcription-coupled repair (TCR), a process whereby DNA damage is preferentially removed from the transcribed strand of active genes (Mellon et al, 1987; van Hoffen et al, 1993) . Although initially described for the removal of UV damage, and therefore considered to be a subpathway of NER, TCR is now recognized as being a more general phenomenon that operates on other kinds of DNA lesions, including oxidative DNA damage (Leadon and Cooper, 1993; Cooper et al, 1997; Nouspikel et al, 1997; Le Page et al, 2000) .
A common pattern has emerged from molecular genetic analyses of the four reported XP-G/CS individuals who suffered from severe early onset CS. All four carried mutations that would have produced truncated XPG proteins Okinaka et al, 1997) . In contrast, two sibling XP-G patients with very mild XP symptoms are able to make full-length XPG containing a single A792V substitution that severely affects the endonuclease activity of XPG (Nouspikel and Clarkson, 1994; Nouspikel et al, 1997; Constantinou et al, 1999) . These results suggest that the XP-G/CS phenotype results from the loss of another important XPG function. Several converging lines of evidence suggest that this additional function is an involvement of XPG in the repair of oxidative DNA damage, both transcription coupled and uncoupled. At one level, XPG stimulates the activity of NTH1, the human DNA glycosylase-apurinic (AP) lyase that removes oxidized pyrimidines from DNA in a distinct base excision repair pathway (Bessho, 1999; Klungland et al, 1999) . Moreover, this stimulation still occurs with a mutated XPG protein that completely lacks the NER endonuclease function (Klungland et al, 1999) . The loss of this cofactor activity may account for the less ef®cient removal of oxidative damage from the genome overall in XP-G/CS patients . Most strikingly, oxidative damage, including thymine glycol and 8-oxoguanine, is removed by TCR in cells from XP-G and normal individuals but not from severely affected XP-G/CS patients Le Page et al, 2000) . It is not yet known how XPG functions in TCR or if it also plays a part in transcription.
The founding member of the XP-G complementation group was described over two decades ago (Cheesbrough, 1978; Keijzer et al, 1979) when the patient, XP2BI, was aged 17 y. She presented freckling, telangiectasia, pigmentation and atrophy on exposed parts, bird-like facies, microcephaly, and mental retardation. Unfortunately, there exist no later clinical records of this patient. The second XP-G individual, XP3BR, was over 7 y old when reported (Arlett et al, 1980) . In addition to the skin changes typical of XP, he exhibited severe mental retardation, severe growth impairment, and dental caries. He died in early adulthood. The potential connection between XP-G and CS was not appreciated at the time these patients were reported but their ages indicate that they did not suffer from the severe early onset form of CS. The bird-like facies of XP2BI and the dental caries of XP3BR, together with the growth defects of both individuals, however, suggest that they might have been affected by a milder form of CS. Here we report the mutations in the XPG gene of these two patients and the effects of these mutations on the ability of XPG to act as an endonuclease in vitro and to repair UV damage in vivo. We discuss their implications for the clinical symptoms of these two patients that are intermediate between mild XP and severe XP/CS.
MATERIALS AND METHODS
Cell strains and culture Primary skin ®broblasts were cultured in minimal essential medium (Seromed, Basel, Switzerland) supplemented with 15% fetal calf serum, 2 mM L-glutamine, 100 U penicillin per ml, and 100 mg streptomycin per ml. Cell strains used were XP2BI and XP3BR (patients), XP124LO and XP125LO (XP-G), XPCS1LV, XPCS2LV, XPCS1RO, XP20BE, and XPCS1BD (XP-G/CS), GM02252 (XP-B/CS, from patient XP11BE), and 250BR (normal control). Lymphoblastoid cells LBL463 from patient XP3BR and Raji cells were cultured in RPMI (Seromed) supplemented with 10% fetal bovine serum, glutamine, and antibiotics.
Nomenclature and subcloning XPG mutations are named according to the recommendations of the Nomenclature Working Group for human gene mutations (Antonarakis, 1998; den Dunnen and Antonarakis, 2000) . Positions in the cDNA sequence are given from the initiating ATG with the A denoted +1.
The 2751delA and 2880±2881del mutations found in patient XP3BR were subcloned as fully sequenced 193 bp BspHI±BbsI fragments into an otherwise wild-type XPG cDNA in pBluescript II KS. The two mutations were combined using unique StuI and BglII sites to give the [2751delA + 2880±2881del] double mutant. The 2573T > C mutation found in patient XP2BI was similarly subcloned into XPG as a 276 bp MfeI±StuI fragment. For use in the vaccinia expression system, the 2751delA, 2880±2881del and [2751delA + 2880±2881del] mutations were transferred into pGEM-XPG (Constantinou et al, 1999) on 1559 bp Bsu36I±NotI fragments. Similarly, a 3386 bp HindIII fragment containing the 2573T > C mutation and most of the coding sequence replaced the corresponding fragment of pGEM-U1A-XPG. In all cases, the presence of the mutations and intact cloning sites were con®rmed after subcloning. For transfection of lymphoblastoid cells, mutant XPG cDNA were cloned into the NotI site of the episomal vector EBO-pLPP (Spickofsky et al, 1990) .
RNA extraction, reverse transcription±polymerase chain reaction (reverse transcription±PCR), and oligonucleotide typing All protocols have been described previously . For oligonucleotide typing, the following g-32 P-adenosine triphosphatelabeled primers were used: 5¢-GACAAAATTCTCTA-3¢ (WT) and 5¢-GACAAATCTCTAAT-3¢ (DAT) for the 2880±2881del mutation, and 5¢-CGATCTTTTCTGTC-3¢ (WT) and 5¢-CGATCTTTCTGTC-3¢ (DA) for 1494delA.
UV survival assays Semicon¯uent ®broblasts were trypsinized and resuspended in culture medium to give a concentration of 0.2±1.0 Q 10 4 cells per ml, depending on their growth rate. Four milliliters of suspension were seeded into each of 12 Petri dishes (6 cm diameter). After 24 h at 37°C, the cells were UV irradiated at 254 nm in Hanks buffer (UV¯uence: 0.125 J per m 2 per s) for various times (two dishes for each dose and four for mock-treated cells). The buffer was replaced by fresh medium which, in turn, was replaced by fresh medium after 4 d. One day later, when the nonirradiated cells had not yet reached con¯uence, the medium was replaced by 3 ml of fresh prewarmed medium containing methyl-3 H-thymidine (20 Ci per mM, 5 mCi per ml) and 20 mM HEPES-KOH (pH 7.3). The cells were incubated at 37°C for 2.5 h, rinsed once with prewarmed PBS then cultured with 4 ml of HEPES medium for a further 01.25 h. The cells were rinsed with PBS, lyzed with 1 ml of fresh 200 mM NaOH, and 0.85 ml of the lysis mixture were mixed with 7.5 ml of scintillation¯uid for scintillation counting (Hamel et al, 1996) .
For UV survival assays of lymphoblasts, the LBL463 cell line was transfected by electroporation with a Gene Pulser (Bio-Rad) at 250 V, 960 mF in RPMI 1640 medium containing 20 mg recombinant DNA per ml and 400 mg Escherichia coli tRNA per ml. Transfectants were selected with increasing doses of hygromycin B (Calbiochem, Lucerne, Switzerland) up to 200 mg per ml. Selected cells were UV-irradiated as described. Quadruplet 200 ml samples containing 10 5 cells were incubated for 46 h at 37°C in 96-well plates. Methyl-3 H-thymidine (1 mCi) was then added to 25 ml medium in each well and incubation was continued for a further 2 h. The plates were frozen, thawed, and the lyzed cells were recovered on glass micro®ber ®lters. After thorough washing, the ®lters were assayed for 3 H content by liquid scintillation counting (Constantinou et al, 1999) .
Protein extracts Cells were washed twice in PBS and proteins were solubilized 30 min at 4°C in a lysis buffer of 50 mM Tris±HCl (pH 7.4), 250 mM NaCl, 5 mM ethylenediamine tetraacetic acid, 0.1% Triton X-100 supplemented with 0.56 mM phenylmethylsulfonyl¯uoride, 2 mg aprotinin per ml, 2 mg leupeptin per ml, and 1 mg pepstatin per ml. Lysates were centrifuged for 20 min at 14,000 Q g and supernatants were recovered. In some experiments, to enrich for XPG, (NH4) 2 SO 4 was added to the extracts. After 20 min on ice, the samples were centrifuged for 20 min at 14,000 Q g. The pellets were washed with saturated (NH4) 2 SO 4 , resuspended in 10 mM Tris±HCl (pH 7.5), and precipitated with 9 vol of 70% acetone, 20% EtOH, 10% 10 mM Tris±HCl (pH 7.5) at ±20°C. Proteins were then pelleted for 30 min at 14,000 Q g and 4°C, and resuspended in 10 mM Tris±HCl (pH 7.5).
Metabolic labeling Raji and LBL463 cells were rinsed once with PBS then incubated overnight with labeling medium containing 9 vol RPMI without methionine and cysteine (Sigma, Buchs, Switzerland), 1 vol complete RPMI, 10% fetal bovine serum, and 100 mCi per ml EasyTag Express protein labeling mix (NEN, Perkin-Elmer, Rotkreug, Switzerland) containing L-35 S-methionine and L-35 S-cysteine. Cells were then washed twice in a large volume of cold PBS and lyzed as described in``Protein extracts''. Lysates were incubated for 2 h at 4°C with 100 ml of protein A Sepharose beads (CL-4B, Amersham Phamacia Biotech, Du Èbendorf, Switzerland) resuspended in NET150NaF buffer containing 50 mM Tris±HCl (pH 8), 150 mM NaCl, 50 mM NaF, and 0.01% nonidet 40. The beads were removed by centrifugation and the lysates were incubated a further 2 h with 100 ml of protein A Sepharose. Beads were removed another time and the supernatants were washed a third time, overnight at 4°C with 150 ml of protein A Sepharose. These clearance steps remove most of the endogenous B cell IgG from the lysates. The supernatants were then incubated overnight at 4°C with or without 4 ml of the anti-XPG 8H7 monoclonal antibody (Evans et al, 1997) . After addition of 50 ml of protein A Sepharose and incubation for 2 h at 4°C, beads were washed four times with 400 ml of NET150NaF. Twenty microliters of sodium dodecyl sulfate gel loading buffer was then added and the samples were then heated for 5 min at 95°C. The supernatants were loaded on a 5% sodium dodecyl sulfate±polyacrylamide gel. After migration, the gel was ®xed, dried, and exposed for 2 d to X-ray ®lm.
Expression of mutated XPG proteins Overexpression of proteins using a recombinant vaccinia virus has been described previously (Constantinou et al, 1999) . Brie¯y, HeLa cells were infected with 5 pfu per cell of vTF7-3, a recombinant vaccinia virus expressing T7 RNA polymerase (Fuerst et al, 1986) . At 1 h postinfection, the medium was replaced with a transfection mix comprising minimal essential medium, 5 mg plasmid DNA, and 15 ml TransfectACE (Rose et al, 1991) . After 3 h at 33°C, minimal essential medium supplemented with 5% fetal bovine serum was added and incubation was continued at 33°C. Cells were harvested 24 h later in PBS, centrifuged at 300 Q g and resuspended in one pellet vol of buffer A containing 50 mM Tris±HCl (pH 8), 300 mM NaCl, and 0.1% nonidet 40 supplemented with 10% glycerol, 1 mM ethylenediamine tetraacetic acid, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl¯uoride, 2 mg leupeptin per ml, and 1 mg pepstatin per ml. The suspension was incubated on ice for 30 min then nuclei were removed from the cytosolic extracts by centrifugation at 14,000 Q g for 20 min.
Western blots Immunoblotting was performed essentially as described . Equivalent cell extracts were boiled for 5 min in sodium dodecyl sulfate gel loading buffer and electrophoresed on 5% polyacrylamide gels. The proteins were transferred to Immobilon-PVDF membranes (Millipore, Mont-sur-Lausanne, Switzerland) using a semidry transfer apparatus (LKB-Instrument AG, Littau-Luzern, Switzerland) at 3 mA per cm 2 of membrane for 45 min Membranes were blocked for 1 h in 3% skim milk in 100 mM Tris±HCl (pH 7.5), 0.9% NaCl, 0.05% Tween 20 (TBS-T) then incubated overnight at 4°C with either the 8H7 monoclonal antibody or a rabbit polyclonal antibody raised against the N-terminus of XPG (O'Donovan et al, 1994b) , both diluted to 1/ 200 in 1% skim milk in TBS-T. Blots were washed 3 Q 15 min in TBS-T then incubated for 1 h with a peroxidase-conjugated anti-mouse or anti-rabbit antibody (Amersham Phamacia Biotech, 1/4000 in 1% skim milk in TBS-T). After three washes of 15 min each in TBS-T, signals were detected using ECL chemiluminescence (Amersham Pharmacia Biotech) and, when necessary, quanti®ed by densitometry (Molecular Dynamics Inc., Du Èbendorf, Switzerland).
Immunopuri®cation, immunoprecipitation, and endonuclease assay These procedures have been described previously (Constantinou et al, 1999) . In brief, XPG proteins were immunopuri®ed by mixing 4 ml of 8H7 antibody with appropriate amounts of HeLa extracts. Volumes were completed to 100 ml with buffer A. After incubation for 1 h at 4°C, the XPG-8H7 antibody complex was coupled with 10 ml of protein A Sepharose beads for 1.5 h at 4°C. Beads were subsequently washed twice in 500 ml of buffer A, then twice in 500 ml of buffer B containing 25 mM HEPES-KOH (pH 6.8), 10% glycerol, 2 mM MgCl 2 , and 1 mM dithiothreitol supplemented with 150 mM KCl, 0.4% nonidet 40, 0.1 mM phenylmethylsulfonyl¯uoride, 2 mg leupeptin per ml, and 1 mg pepstatin per ml, and ®nally resuspended in 20 ml buffer B for use in the endonuclease assay. The``bubble'' substrate used in this assay comprises two partially complementary 90-mer oligonucleotides with a central 30 nt unpaired region (O'Donovan et al, 1994a; Constantinou et al, 1999) . One strand was previously 5¢-labeled with polynucleotide kinase and g-32 P-adenosine triphosphate. Substrate (0.2±0.5 ng) was incubated with the immunopuri®ed sample for 3 h at 37°C. Reactions were stopped by addition of 30 mM ethylenediamine tetraacetic acid, 0.6% sodium dodecyl sulfate, and 0.4 mg per ml proteinase K. After 30 min at 37°C, phenol extraction and ethanol precipitation, samples were resuspended in formamide dye mix, heated at 95°C and loaded on to denaturing 12% polyacrylamide gels.
RESULTS
XP2BI and XP3BR ®broblasts are highly UV sensitive The UV sensitivities of primary ®broblasts from these two patients were compared with those of ®broblasts from a normal individual, two XP-G patients: XP124LO and XP125LO (Norris et al, 1987) , and four XP-G/CS patients: XPCS1LV and XPCS2LV (Jaeken et al, 1989; Vermeulen et al, 1993) , XP20BE (Moriwaki et al, 1996) and XPCS1RO, who was previously referred to as 94RD27 (Hamel et al, 1996; Nouspikel et al, 1997) . Figure 1A shows 3 H-thymidine incorporation of the wild-type and mutant ®broblasts 5 d after UV irradiation. Cells from patients XP124LO and XP125LO (siblings affected by the same mutations) show only modest UV sensitivity due to some residual activity of their A792V mutant XPG protein (Constantinou et al, 1999) . In contrast, all four XP-G/CS cells are highly UV sensitive. They all encode truncated XPG proteins that presumably are devoid of endonuclease activity Okinaka et al, 1997) . Figure 1B shows the same experiment performed on XP2BI and XP3BR ®broblasts. Both ®t into the XP-G/CS pattern and they behave as if they have little if any XPG endonuclease activity.
Mutations in the XPG gene of XP2BI For molecular genetic analysis, total RNA was isolated from XP2BI ®broblasts, reversed transcribed, and the » 3.6 kb XPG cDNA was ampli®ed by PCR. The products were cloned in a plasmid vector and several clones were sequenced. Both XPG alleles carry two known polymorphisms (Nouspikel and Clarkson, 1994; Emmert et al, 2001 ): a silent T±C transition at position 138 (H46) and a C to G transversion at position 3310 (H1104D). One allele contains a single point mutation, a T±C transition at position 2573, which replaces leucine 858 with a proline. Its existence was con®rmed by sequencing XP2BI genomic DNA that revealed the presence of both C and T at this position (Fig 2A) . This leucine is located within the evolutionary conserved I region that is thought to form part of the XPG endonuclease active site (Constantinou et al, 1999) . The existence of 2573T > C was also independently con®rmed by digestion of reverse transcription±PCR and genomic PCR products with the enzyme BstNI, for which a new site is created by the mutation (Fig 2C) . This allele would also express the H1104D polymorphism but this is unlikely to have functional signi®cance because XPG cDNA carrying D1104 can restore UV resistance to XPG-defective mouse and human cells (MacInnes et al, 1993; Shiomi et al, 1994) . Moreover, a recent screen of 91 non-XP individuals showed D1104 to be » 3-fold more frequent than H1104 (Emmert et al, 2001) .
The other XPG allele in XP2BI contains a 4 nt deletion (AGGA) from positions 1114 to 1117. This creates a frameshift resulting in a truncated protein of 376 amino acids, the last ®ve being unrelated to XPG. The existence of 1114±1117delAGGA was con®rmed by sequencing XP2BI genomic DNA that revealed the expected sequence doublets from position 1114 (Fig 2B) . The deletion creates a new site for the restriction enzyme HgaI, which was experimentally con®rmed by digestion of reverse transcription±PCR and genomic PCR products (Fig 2D) . In addition, the same allele carries another silent polymorphism, a C±T transition at position 960 (D320), as well as an A±G transition at position 2636 that would result in a N879S substitution; however, the protein is truncated upstream of this point, so presumably this mutation has no functional consequence. Figure 2E schematizes the mutant XPG proteins encoded by XP2BI cells.
Mutations in the XPG gene of XP3BR The same procedure was applied to XP3BR primary ®broblasts and to LBL463 lymphoblastoid cells from this patient. In this case, the two XPG alleles can be distinguished by the H1104D polymorphism. The allele encoding an Asp is missing one A residue within an A4 stretch at positions 1491±1494. The resulting frameshift generates a truncated protein of 521 amino acids, the last 23 being unrelated to XPG. The existence of this deletion was con®rmed by sequencing XP3BR genomic DNA that revealed the expected sequence doublets from position 1491 (Fig 3A) , and by hybridization of XP3BR reverse transcription±PCR and genomic PCR products with oligonucleotide probes speci®c for the mutated and the wildtype sequences (Fig 3C) .
The other XPG allele in XP3BR lacks one A within an A9 stretch at positions 2743±2751. This results in a truncated protein of 980 amino acids, the last 64 being unrelated to XPG. The existence of this deletion was con®rmed by sequencing XP3BR genomic DNA that revealed the expected sequence doublets from position 2743 (Fig 3B) . Owing to the length of the A tract, independent con®rmation of the mutation was not possible by restriction or differential hybridization analyses, but the 2751delA mutation was found in 10 independent clones from LBL463 lymphoblasts and in ®ve independent clones from primary ®broblasts. Interestingly, an intron is located in between the deletion and the termination codon resulting from the frameshift. The splice donor and acceptor sites of this intron do not correspond to the canonical GT±AG consensus sequences, but instead they resemble the motifs found in a rare class of U12-dependent AT±AC introns (Tarn and Steitz, 1997) . The donor site exactly matches the ATATCCTT motif but the acceptor site contains TGCAT instead of YCCAC (Fig 3E) . This may help to explain the production of a minor alternative splicing event that removes the ®rst two nucleotides from the following exon (2880±2881del; Fig 3E) . The existence of such aberrant splicing was con®rmed by hybridization of reverse transcription±PCR products from XP3BR cells with oligonucleotide probes speci®c for the normal and abnormal splice products (Fig 3D) . For this patient, the combination of this splicing event with the single nucleotide deletion in position 2751 would restore the reading frame and thereby generate an almost full-length XPG protein of 1185, instead of 1186 amino acids. Such a protein would contain an internal stretch of 44 amino acids unrelated to XPG. For simplicity, this K917fs962fsX1186 protein is hereinafter referred to as 917fs962fs. Figure 3F schematizes the mutant XPG proteins potentially produced in XP3BR cells. (E) Schematic diagram of wild-type XPG and of mutant XPG proteins encoded by XP2BI ®broblasts. N, I, C, and NLS indicate the conserved N-terminal, internal and basic C-terminal regions, and putative nuclear localization signal, respectively. Nomenclature follows current recommendations (Antonarakis, 1998; den Dunnen and Antonarakis, 2000) .
Mutant 917fs962fs XPG protein is expressed in XP3BR cells
To determine if the predicted 917fs962fs XPG protein is indeed produced and stable in XP3BR cells, western blots were done on LBL463 lymphoblast extracts from this patient. As shown previously for XP-G patients XP124LO and XP125LO, it is dif®cult to detect a decreased endogenous level of XPG in crude extracts of lymphoblasts . Therefore, two approaches were taken to enhance the detection of XPG. In the ®rst, extracts from XP3BR (LBL463) and from an XP-B/CS patient (as XPG positive control) were precipitated with ammonium sulfate before electrophoresis to increase the ratio of XPG to total protein. Wild-type XPG is readily detected in the enriched XP-B/CS extract ( Fig 4A) with a polyclonal rabbit antibody to the N-terminus of XPG (O'Donovan et al, 1994b) . XPG migrates near the 205 kDa marker , probably because of its acidic nature (Scherly et al, 1993) . A faint band of comparable length is also found in the enriched XP3BR extracts (Fig 4A) , indicating the presence of the 917fs962fs XPG protein. In the second approach, LBL463 and wild-type Raji lymphoblasts were labeled with 35 S-methionine and 35 S-cysteine and the cell extracts were then immunoprecipitated with 8H7, a mouse monoclonal antibody to XPG (Evans et al, 1997) . XPG bands of comparable length are detectable in both extracts after addition of the antibody (Fig 4B) . We conclude that alternative splicing of pre-mRNA from one XPG allele permits production of the almost full-length 917fs962fs XPG protein in XP3BR lymphoblasts. Presumably this is also true for other cell types but we have not been able to demonstrate XPG in XP3BR ®broblasts because of the lower ratio of XPG to total protein in this cell type (data not shown). We have also not been able to detect the L858P XPG protein in extracts of XP2BI ®broblasts and, unfortunately, no lymphoblastoid cell line exists for this patient.
Mutant L858P and 917fs962fs XPG proteins have severely diminished endonuclease activity To test intrinsic XPG endonuclease activity, wild-type XPG, the L858P and 917fs962fs mutants, and CSB as a negative control were overexpressed in HeLa cells using a vaccinia virus-based expression system (Constantinou et al, 1999) . As shown by western blotting (Fig 5C) , the amount of endogenous HeLa XPG in the extracts (CSB lane) is negligible relative to the overexpressed wild-type and mutant XPG proteins. Equivalent 1:2:3 amounts of wild-type and mutant proteins were then mixed with the 8H7 anti-XPG Figure 4 . Detection of the K917fs962fsX1186 XPG protein in XP3BR lymphoblasts. (A) Lymphoblastoid cells from XP3BR (LBL463) and XP11BE (an XP-B/CS patient used as a control) were lyzed and submitted to western blotting using a polyclonal antibody to the N-terminus of XPG. Lanes 1 and 4 contained 200 mg of total protein. For lanes 2 and 5, and lanes 3 and 6, 400 mg total proteins were submitted to 40% or 50% ammonium sulfate precipitation, respectively, prior to gel electrophoresis. (B) LBL463 and control Raji lymphoblasts were labeled overnight with L-35 S-methionine and L-35 S-cysteine, protein extracts were prepared and immunoprecipitated with (+) or without (±) the 8H7 anti-XPG monoclonal antibody prior to gel electrophoresis. The arrows in both panels show the locations of the 1186 amino acid wild-type XPG and the 1185 amino acid mutant protein. (2751delA) generates a frameshift and a truncated protein of 980 amino acids (K917fsX981). In both panels, the wild-type genomic sequence is shown above and the mutation is shown below the sequence. (C) Con®rmation of 1494delA mutation by hybridization of reverse transcription±PCR (mRNA) and genomic PCR (DNA) products with oligonucleotide probes speci®c for the mutated (DA) or wild-type (WT) sequences. Plasmid DNA with or without the mutation were used to con®rm the speci®cities of the probes. (D) Con®rmation of the aberrantly spliced 2880± 2881del mutation using the same technique and appropriate DAT oligonucleotide probe. (E) Exon±intron 13 boundaries in wild-type XPG and in the 2751delA allele from XP3BR. The combination of the 2751delA and 2880±2881del deletions generates a 1185 residue XPG protein containing an internal stretch of 44 aberrant amino acids (K917fs962fsX1186). (F) Summary of XPG proteins encoded by XP3BR cells. monoclonal antibody coupled to protein A Sepharose beads, and the immobilized XPG proteins were incubated with a radiolabeled bubble substrate as previously described (Constantinou et al, 1999) . Structure-speci®c endonuclease activity releases a major labeled 61 nt product from this substrate (O'Donovan et al, 1994a). As expected, the overexpression of wild-type XPG protein results in a much higher activity than that of the endogenous XPG (compare lanes 4±6 with lanes 1±3, Fig 5B) . In contrast, neither the L858P nor 917fs962fs mutant protein shows any detectable activity in this in vitro assay, despite being more abundant than the endogenous XPG protein (compare lanes 7±9 and lanes 10±12 with lanes 1±3, Fig 5B) . We conclude that, in isolation, these mutant XPG proteins are unable to act as structure-speci®c endonucleases.
To investigate the consequences of the mutations on in vivo activity, XPG cDNA containing the wild-type sequence, 2573T > C or the double mutation [2751delA + 2880±2881del] were cloned into an episomal vector and were electroporated into LBL463 lymphoblastoid cells from patient XP3BR. As the 2751delA mutation and 2880±2881del alternative splice can occur independently, they were also cloned separately and introduced into LBL463 cells. Stable transfectants were selected and cell survival was assayed by 3 H-thymidine incorporation 48 h after UV treatment. Cells expressing the 2751delA or 2880± 2881del frameshift mutations are extremely UV sensitive, just as sensitive as cells transfected with the vector alone (Fig 6) . The combination of both mutations, which permits expression of almost full-length XPG, does not improve UV resistance; if anything, it reduces it even further (Fig 6) . Transfectants carrying the 2573T > C transition are slightly more UV resistant than the other mutants but at 10 J per m 2 are at least 50-fold more UV sensitive than transfectants expressing wild-type XPG (Fig 6) .
To assess the production and stability of these various XPG proteins, western blots were done on the LBL463 transfectants. Both wild-type XPG and the 917fs962fs mutant encoded by [2751delA + 2880±2881del] cDNA are produced in normal amounts in the relevant transfectants (data not shown); however, we have never been able to detect L858P protein in 2573T > C transfectants (data not shown), even though L858P is readily detected in HeLa cells with the vaccinia virus-based expression system ( Fig 5C) . A possible reason for this apparent discrepancy is discussed below. We conclude that the key full-length and almost full-length mutant XPG proteins produced in XP2BI and XP3BR cells, L858P and 917fs962fs, respectively, would severely compromise in vivo NER activity.
DISCUSSION
The molecular genetic evidence in this study shows that the ®rst two reported XP-G patients, XP2BI and XP3BR, are compound heterozygotes with different mutations in each XPG allele. Table I summarizes the mutations and polymorphisms found in each allele, together with their resulting XPG protein products. In XP3BR, one allele generates a 521 amino acid protein instead of full-length XPG of 1186 amino acids (Fig 3) . This truncated protein lacks the highly conserved I-region that is thought to juxtapose with the N-region to form the active site of this structure-speci®c endonuclease (Constantinou et al, 1999) . Although it was not tested for activity, this protein is expected to be nonfunctional because a less severe truncation inactivates NER in vivo (Nouspikel and Clarkson, 1994) .
The second XPG allele in XP3BR produces a truncated protein of 980 amino acids that retains both the conserved N-and I-regions; however, XP-G transfectants expressing this mutated allele are still extremely UV sensitive (Fig 6) . This indicates that this mutant XPG protein is unable to act ef®ciently in NER, for which there are several possible explanations. Having lost the nuclear localization signal near the C-terminus (Fig 3) , it may not Figure 5 . The full-length and almost full-length XPG proteins produced in XP2BI and XP3BR cells are devoid of intrinsic structure-speci®c endonuclease activity. (A) Schematic representation of the pull down endonuclease assay. (C) After expression in vTF7-3-infected HeLa cells transfected with cDNA for CSB as a negative control, wild-type XPG, or the two mutated XPG proteins, lysates were electrophoresed on a 5% polyacrylamide gel, blotted and probed with the mouse anti-XPG monoclonal antibody 8H7. (B) The autoradiograph in panel C was scanned to evaluate the amount of XPG relative to the total protein concentration in each HeLa extract. Equivalent 1:2:3 ratios of XPG were immunopuri®ed from appropriate amounts of the extracts and incubated for 3 h with a bubble substrate 5¢-labeled on one strand. The products of the endonuclease reactions were analyzed on a denaturing 12% polyacrylamide gel. be able to enter the nucleus. Even if transported to the nucleus, an altered conformation may prevent it being positioned correctly in the NER incision complex and/or prevent it functioning as an endonuclease despite its retention of the N-and I-regions. In isolation, this truncated protein has no detectable structure-speci®c endonuclease activity (Fig 5) , which suggests the likelihood of at least this third possibility.
The second XPG allele from XP3BR also generates another mutated form of XPG through alternative splicing of a rare AT±AC intron (Tarn and Steitz, 1997) . The combination of the single nucleotide deletion 2751delA and the loss of the ®rst two nucleotides from the downstream exon 14 (Emmert et al, 2001; Pigni, 2001 ) restores the open reading frame and produces a protein of 1185 amino acids, 44 of which are unrelated to XPG (Fig 3) . This mutant 917fs962fs protein retains the N-and I-regions, the nuclear localization signal, and the basic C-terminus of XPG; however, it has no detectable intrinsic structure-speci®c endonuclease activity (Fig 5) , presumably due to the presence of non-XPG sequences near the C-terminal boundary of the I-region. Consistent with its lack of activity in vitro, XP-G transfectants expressing the mutant 917fs962fs protein are at least as UV sensitive as XP-G cells transfected with the vector alone (Fig 6) . We conclude that, although this almost full-length mutant XPG protein is stably expressed in XP3BR (Fig 4) , it has little if any NER activity, thereby contributing to the UV sensitivity of cells from this patient (Fig 1) .
In XP2BI, one XPG allele is missing the four nucleotides from positions 1114 to 1117. This causes a frameshift that results in a protein of 376 amino acids, the last ®ve being unrelated to XPG (Fig 2) . This is an even more severe truncation than the shortest XPG protein produced in XP3BR and it is therefore expected to be inactive. This allele also encodes a N879S substitution that presumably is without functional signi®cance because it is located C-terminal to the truncation.
The second and more interesting XPG allele from XP2BI contains the H1104D polymorphism and a single pyrimidine transition that results in a L858P substitution in the conserved I-region (Fig 2) . In isolation, this mutant XPG protein exhibits no structure-speci®c endonuclease activity (Fig 5) , but XP-G transfectants expressing the L858P protein are slightly more UV resistant than transfectants carrying the EBO-pLPP vector alone (Fig 6) . This suggests that the L858P XPG protein does have some very slight endonuclease activity but that the presence of other NER components is required for this to be revealed. XPG proteins with deliberately created acidic substitutions in the N-and I-regions (D77E and E791D, respectively) behave in a similar way (Constantinou et al, 1999) .
The mutant L858P XPG protein is readily detected when expressed in HeLa cells with the vaccinia virus system (Fig 5C) but we have never been able to ®nd it by western blotting in transfected XP-G lymphoblasts (data not shown). These two cell systems are very different, however. The vaccinia system generates huge amounts of protein ( Fig 5C) and, moreover, in a context in which much of the normal cell machinery is short-circuited by the virus. In particular, it is likely that normal degradative as well as synthetic pathways are defective. In contrast, wild-type protein levels are produced from the SV40 early promoter in the XPG EBO-pLPP recombinants transfected into XP-G lymphoblasts (data not shown). Together, these results suggest that the mutant L858P protein does have some slight residual NER endonuclease activity but that it is also less stable than wild-type XPG. The net result is that this full-length mutant XPG protein contributes to the severe UV sensitivity of XP2BI cells (Fig 1) .
Four mutated forms of XPG thus contribute to the XP clinical phenotypes of patients XP2BI and XP3BR: two truncated proteins, a stable almost full-length protein containing an internal stretch of non-XPG residues, and full-length XPG of reduced stability containing an amino acid substitution in the conserved I-region. The clinical symptoms may arise through the suboptimal presence of these proteins, particularly during early development, as well as their reduced biologic activity. In addition, polymorphisms in other genes may contribute to the diverse clinical manifestations of these two patients. None of the mutated forms of XPG can act ef®ciently as the 3¢ endonuclease in NER. These four proteins can thus account for the severe UV sensitivities of XP2BI and XP3BR ®broblasts, which clearly overlap those of XP-G/CS rather than XP-G cells (Fig 1) ; however, neither patient was affected by early onset CS, although there are hints that both may have been affected by a milder form of CS. Recently, XP2BI and XP3BR ®broblasts have been found to be capable of limited TCR of oxidative DNA damage (Le Page et al, 2000) . Our results suggest that the L858P protein in XP2BI and the almost full-length 917fs962fs XPG protein in XP3BR are responsible for this activity, and that as a consequence they prevent the development of severe early onset CS symptoms in these patients.
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d D is most frequently found at this position (Emmert et al, 2001 ).
e Downstream from the truncation.
